Literature DB >> 18523647

To kill a tumor cell: the potential of proapoptotic receptor agonists.

Avi Ashkenazi1, Roy S Herbst.   

Abstract

Disturbances in mechanisms that direct abnormal cells to undergo apoptosis frequently and critically contribute to tumorigenesis, yielding a logical target for potential therapeutic intervention. There is currently heightened interest in the extrinsic apoptosis pathway, with several proapoptotic receptor agonists (PARAs) in development. The PARAs include the ligand recombinant human Apo2L/TRAIL and agonistic mAbs. Mechanistic and preclinical data with Apo2L/TRAIL indicate exciting opportunities for synergy with conventional therapies and for combining PARAs with other molecularly targeted agents. Novel molecular biomarkers may help identify those patients most likely to benefit from PARA therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18523647      PMCID： PMC2396896          DOI： 10.1172/JCI34359

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  116 in total

1.  Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.

Authors:  Karthikeyan Kandasamy; Srinivasa M Srinivasula; Emad S Alnemri; Craig B Thompson; Stanley J Korsmeyer; Joseph L Bryant; Rakesh K Srivastava
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

2.  IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.

Authors:  L M Sedger; D M Shows; R A Blanton; J J Peschon; R G Goodwin; D Cosman; S R Wiley
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

3.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

Authors:  C S Mitsiades; S P Treon; N Mitsiades; Y Shima; P Richardson; R Schlossman; T Hideshima; K C Anderson
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

4.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  Susan O'Brien; Joseph O Moore; Thomas E Boyd; Loree M Larratt; Aleksander Skotnicki; Benjamin Koziner; Asher A Chanan-Khan; John F Seymour; R Gregory Bociek; Steve Pavletic; Kanti R Rai
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

5.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

6.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

Authors:  Edith M Janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas S Griffith; Douglas R Green; Stephen P Schoenberger
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

7.  TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.

Authors:  W D Thomas; P Hersey
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

8.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Authors:  Anthony W Tolcher; Monica Mita; Neal J Meropol; Margaret von Mehren; Amita Patnaik; Kristin Padavic; Monique Hill; Theresa Mays; Therese McCoy; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Roger B Cohen
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

Review 9.  The role of the Bcl-2 protein family in cancer.

Authors:  Leigh Coultas; Andreas Strasser
Journal:  Semin Cancer Biol       Date:  2003-04       Impact factor: 15.707

10.  Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.

Authors:  Subrata Ray; Alex Almasan
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701
View more
  126 in total

1.  Protection of porcine endothelial cells against apoptosis with interleukin-4.

Authors:  Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

2.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

Review 3.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

4.  Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.

Authors:  Alan D Brooks; Kristen M Jacobsen; Wenqing Li; Anil Shanker; Thomas J Sayers
Journal:  Mol Cancer Res       Date:  2010-05-04       Impact factor: 5.852

Review 5.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

6.  Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Authors:  Josep Tabernero; Sant P Chawla; Hedy Kindler; Karen Reckamp; E Gabriela Chiorean; Nilofer S Azad; A Craig Lockhart; Cheng-Pang Hsu; Nigel F Baker; Francesco Galimi; Pedro Beltran; José Baselga
Journal:  Target Oncol       Date:  2014-05-11       Impact factor: 4.493

Review 7.  Apoptotic pathways as a therapeutic target for colorectal cancer treatment.

Authors:  Aman M Abraha; Ezra B Ketema
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

8.  TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells.

Authors:  Daniel Borja-Cacho; Yumi Yokoyama; Rohit K Chugh; Nameeta R Mujumdar; Vikas Dudeja; Kimberly A Clawson; Rajinder K Dawra; Ashok K Saluja; Selwyn M Vickers
Journal:  J Gastrointest Surg       Date:  2009-12-16       Impact factor: 3.452

9.  The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway.

Authors:  Shayna E Oshita; Feng Chen; Toni Kwan; Fruma Yehiely; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2010-01-20       Impact factor: 4.872

10.  EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.

Authors:  Henrick Horita; Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Journal:  J Neurooncol       Date:  2009-05-17       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.